Strategies to improve long-term outcomes after renal transplantation

New England Journal of Medicine

Volumn 346, Issue 8, 2002, Pages 580-590

  Pascual, Manuel ^a   Theruvath, Tom ^a   Kawai, Tatsuo ^a   Tolkoff Rubin, Nina ^a   Benedict Cosimi, A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; CHRONIC DISEASE; DRUG MECHANISM; GRAFT FAILURE; HISTOPATHOLOGY; HLA MATCHING; HLA SYSTEM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONG TERM CARE; NEPHROTOXICITY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CALCINEURIN; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 0037148938     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra011295     Document Type: Review

References (99)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Renal transplantation
3. Chronic rejection and chronic cyclosporin toxicity in renal allografts
4. Immunosuppressive strategies in transplantation
5. Risk factors for chronic rejection in renal allograft recipients
6. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
7. Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion
8. The renal allograft biopsy
9. Why do we reject a graft? Role of indirect allorecognition in graft rejection
10. Clinical predictors of chronic renal allograft rejection
11. Humoral antibodies in renal allotransplantation in man
12. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation
13. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection
14. Chronic humoral rejection: Identification of antibody mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries
15. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection
16. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group
17. Association of chronic kidney graft failure with recipient blood pressure: Collaborative Transplant Study
18. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection
19. A novel approach to the treatment of chronic allograft nephropathy
20. Evolution and etiology of cardiovascular diseases in renal transplant recipients
21. Kidney transplant recipients who die with functioning grafts: Serum creatinine level and cause of death
22. Long-term survival in renal transplant recipients with graft function
23. Time dependency of factors affecting renal allograft survival
24. Explained and unexplained ischemic heart disease risk after renal transplantation
25. Delayed graft function in renal transplantation: Etiology, management and long-term significance
26. Acute renal failure
27. Organ preservation
28. Living unrelated donor kidney transplantation
29. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation
30. Living unrelated donors in kidney transplants: Better long-term results than with non-HLA-identical living related donors?
31. Infection in organ- transplant recipients
32. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double blind, clinical studies in prevention of rejection
33. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
34. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
35. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
36. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study
37. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
38. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
39. Tacrolimus in renal transplantation
40. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study
41. Immunosuppressants: Cellular and molecular mechanisms of action
42. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo controlled trial
43. Mycophenolate mofetil in cadaveric renal transplantation
44. A blinded, long-term, randomized multicenter study ofmycophenolate mofetil in cadaveric renal transplantation: Results at three years
45. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
46. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts
47. Sirolimus and cyclosporin for renal transplantation
48. Pharmacokinetics and pharmacodynamics of sirolimus
49. Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions
50. Sirolimus-tacrolimus combination immunosuppression
51. Targeting the interleukin-2 receptor in clinical renal transplantation
52. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts
53. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation
54. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation
55. Tacrolimus rescue therapy for renal allograft rejection - Five-year experience
56. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection
57. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics
58. Chronic immunosuppression of the renal transplant patient
59. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): A multicenter, randomised, controlled study
60. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction
61. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation
62. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
63. Long-term outcome of a prospective trial of steroid withdrawal after kidney transplantation
64. Trends in the use of glucocorticoids in renal transplantation
65. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
66. A meta-analysis of immunosuppression withdrawal trials in renal transplantation
67. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
68. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients
69. Protecting single-kidney allografts from long-term functional deterioration
70. Hypertension after renal transplantation
71. Renal transplantation
72. Renoprotective efficacy of antihypertensive drugs in chronic renal allograft nephropathy
73. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism
74. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
75. Hyperlipidemia in solid organ transplantation
76. Treatment of hyperlipidemia in renal transplant recipients
77. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
78. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
79. Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids
80. A calcineurin antagonist-free induction strategy, for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function
81. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: Results of a prospective pilot study in 28 consecutive cases
82. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
83. Cyclosporine avoidance
84. 'Actively acquired tolerance' of foreign cells
85. Tolerance to vascularized organ allografts in large-animal models
86. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors
87. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation
88. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
89. Mixed chimerism as an approach for the induction of transplantation tolerance
90. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance
91. Combined histocompatibility leukocyte antigen -matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism
92. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism
93. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients
94. Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients
95. Six-year clinical effect of donor bone marrow infusions in renal transplant patients
96. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
97. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig and anti-CD40 ligand
98. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
99. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine